siRNA  ||| S:0 E:6 ||| NNP
and  ||| S:6 E:10 ||| CC
miRNA  ||| S:10 E:16 ||| JJ
for  ||| S:16 E:20 ||| IN
the  ||| S:20 E:24 ||| DT
treatment  ||| S:24 E:34 ||| NN
of  ||| S:34 E:37 ||| IN
cancer  ||| S:37 E:44 ||| NN
In  ||| S:44 E:47 ||| IN
the  ||| S:47 E:51 ||| DT
process  ||| S:51 E:59 ||| NN
of  ||| S:59 E:62 ||| IN
RNA  ||| S:62 E:66 ||| NNP
interference  ||| S:66 E:79 ||| NN
( ||| S:79 E:80 ||| -LRB-
RNAi ||| S:80 E:84 ||| NNP
) ||| S:84 E:85 ||| -RRB-
,  ||| S:85 E:87 ||| ,
small  ||| S:87 E:93 ||| JJ
RNAs  ||| S:93 E:98 ||| JJ
pair  ||| S:98 E:103 ||| NN
with  ||| S:103 E:108 ||| IN
complementary  ||| S:108 E:122 ||| JJ
messenger  ||| S:122 E:132 ||| NN
RNAs  ||| S:132 E:137 ||| NN
preventing  ||| S:137 E:148 ||| VBG
their  ||| S:148 E:154 ||| PRP$
expression ||| S:154 E:164 ||| NN
.  ||| S:164 E:166 ||| .
The  ||| S:166 E:170 ||| DT
discovery  ||| S:170 E:180 ||| NN
of  ||| S:180 E:183 ||| IN
RNAi  ||| S:183 E:188 ||| NNP
has  ||| S:188 E:192 ||| VBZ
revolutionized  ||| S:192 E:207 ||| VBG
our  ||| S:207 E:211 ||| PRP$
understanding  ||| S:211 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
gene  ||| S:228 E:233 ||| NN
regulation ||| S:233 E:243 ||| NN
.  ||| S:243 E:245 ||| .
Since  ||| S:245 E:251 ||| IN
cancer  ||| S:251 E:258 ||| NN
is  ||| S:258 E:261 ||| VBZ
a  ||| S:261 E:263 ||| DT
disease  ||| S:263 E:271 ||| NN
of  ||| S:271 E:274 ||| IN
altered  ||| S:274 E:282 ||| JJ
genes ||| S:282 E:287 ||| NNS
,  ||| S:287 E:289 ||| ,
RNAi  ||| S:289 E:294 ||| NNP
may  ||| S:294 E:298 ||| MD
have  ||| S:298 E:303 ||| VB
tremendous  ||| S:303 E:314 ||| JJ
potential  ||| S:314 E:324 ||| NN
as  ||| S:324 E:327 ||| IN
a  ||| S:327 E:329 ||| DT
therapeutic  ||| S:329 E:341 ||| JJ
strategy  ||| S:341 E:350 ||| NN
by  ||| S:350 E:353 ||| IN
downregulating  ||| S:353 E:368 ||| JJ
altered  ||| S:368 E:376 ||| JJ
genes ||| S:376 E:381 ||| NNS
.  ||| S:381 E:383 ||| .
Just  ||| S:383 E:388 ||| RB
one  ||| S:388 E:392 ||| CD
decade  ||| S:392 E:399 ||| NN
after  ||| S:399 E:405 ||| IN
its  ||| S:405 E:409 ||| PRP$
discovery ||| S:409 E:418 ||| NN
,  ||| S:418 E:420 ||| ,
this  ||| S:420 E:425 ||| DT
process  ||| S:425 E:433 ||| NN
is  ||| S:433 E:436 ||| VBZ
already  ||| S:436 E:444 ||| RB
being  ||| S:444 E:450 ||| VBG
used  ||| S:450 E:455 ||| VBN
in  ||| S:455 E:458 ||| IN
clinical  ||| S:458 E:467 ||| JJ
trials  ||| S:467 E:474 ||| NNS
and  ||| S:474 E:478 ||| CC
new  ||| S:478 E:482 ||| JJ
technical  ||| S:482 E:492 ||| JJ
achievements  ||| S:492 E:505 ||| NNS
in  ||| S:505 E:508 ||| IN
delivering  ||| S:508 E:519 ||| VBG
small  ||| S:519 E:525 ||| JJ
RNAs  ||| S:525 E:530 ||| JJ
to  ||| S:530 E:533 ||| TO
the  ||| S:533 E:537 ||| DT
cells  ||| S:537 E:543 ||| NNS
are  ||| S:543 E:547 ||| VBP
constantly  ||| S:547 E:558 ||| RB
improving  ||| S:558 E:568 ||| VBG
the  ||| S:568 E:572 ||| DT
efficiency  ||| S:572 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
this  ||| S:586 E:591 ||| DT
specific  ||| S:591 E:600 ||| JJ
cancer  ||| S:600 E:607 ||| NN
treatment ||| S:607 E:616 ||| NN
.  ||| S:616 E:618 ||| .
